Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer — Stella

Home/Locally Advanced Breast Cancer/Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer

View on ClinicalTrials.gov

Recruiting

Back to Locally Advanced Breast Cancer trials

Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

China

Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai Municipality

Key details

Phase

Large-scale testing

Sponsor

RenJi Hospital

Enrollment target

~316 participants

Started

December 2019

Primary completion

August 2026

Age range

18 Years – 70 Years

Sex

Female only

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.